All Fulcrum Publications

October 30, 2019

Design of a biomarker of DUX4 activity to evaluate losmapimod treatment effect in FSHD Phase 2 trials

Lucienne Ronco, Diego Cadavid, Jayashree Chadchankar, Aaron Chang, Michelle Mellion, Alan Robertson, Alejandro Rojas, Ning Shen, Rabi Tawil, Stephen Tapscott, Leo Wang, Owen Wallace

October 16, 2019

Phase 1 clinical trial of losmapimodin FSHD: safety, tolerability and target engagement

Michelle L. Mellion, Lucienne Ronco, Drew Thompson, Michelle Hage, Sander Brooks, Emilie van Brummelen, Lisa Pagan, Umesh Badrising, William Tracewell, Shane Raines, Baziel van Engelen, Geert Jan Groeneveld, Diego Cadavid

October 4, 2019

Safety and tolerability of losmapimod, a selective p38a/b MAPK inhibitor, for treatment of FSHD at its root cause

Diego Cadavid, Michelle Mellion, Owen Wallace, Lucienne Ronco, Drew Thompson, Alejandro Rojas, Michelle Hage, Robert Gould

October 4, 2019

Targeting DUX4, the Root Cause of FSHD: Identification of a Drug Target and Development Candidate

Owen Wallace, Anthony Accorsi, Richard Barnes, Angela Cacace, Diego Cadavid, Aaron Chang, Robert Gould, Steven Kazmirski, Joseph Maglio, Michelle Mellion, Peter Rahl, Alan Robertson, Alejandro Rojas, Lucienne Ronco, Ning Shen, Lorin A. Thompson and Erin Valentine, Fulcrum Therapeutics.

June 20, 2019

Losmapimod Reduces DUX4 Expression Across Genotypes in FSHD Patient-Derived Myotubes

Alejandro Rojas, Erin Valentine, Joseph Maglio, Anthony Accorsi, Alan Robertson, Ning Shen, Angela Cacace, Lucienne Ronco, Owen Wallace. Fulcrum Therapeutics.

June 20, 2019

Phase 1 Clinical Trial of Losmapimod in FSHD

Michelle L. Mellion [1], Lucienne Ronco [1], Drew Thompson [1], Michelle Hage [1], William Tracewell [1], Sander Brooks [2], Emilie van Brummelen [2], Lisa Pagan [2], Umesh Badrising [3], Baziel Van Engelen [4], Geert Jan Groeneveld [2,3], Diego Cadavid [1]
[1] Fulcrum Therapeutics, Cambridge, MA, USA, [2] Centre for Human Drug Research (CHDR), Leiden, NL, [3] Leiden University Medical Centre, Leiden, NL, [4] Radboud University Medical Centre, Nijmegen, NL

June 20, 2019

Safety and tolerability of losmapimod, a selective p38α/β MAPK inhibitor, for treatment of FSHD at its root cause

Diego Cadavid, Michelle Mellion, Owen Wallace, Lucienne Ronco, Drew Thompson, Alejandro Rojas, Michelle Hage, Robert Gould. Fulcrum Therapeutics.